Kangtai Biotech: Record of Investor Relations Activities from September 3 to September 4, 2024
Kangtai Biotech: Announcement of Supervisory Board Resolutions
Kangtai Biotech: 2024 Semi-Annual Report Summary
Kangtai Biotech: Special Report on the Deposit and Use of Funds Raised for the 2024 Semi-Annual Year
Kangtai Biotech: Announcement on preparations for asset impairment accrued for the semi-annual period of 2024
Kangtai Biotech: Announcement of Board Resolutions
Kangtai Biotech: Summary table on the use of non-operating capital and other related capital transactions for the first half year of 2024
Kangtai Biotech: 2024 Semi-Annual Report
Kangtai Biotech: Announcement on progress of wholly-owned subsidiaries providing guarantees to the company
Shenzhen Kangtai Biological Products: Announcement on the approval of drug clinical trial approval for quadrivalent influenza virus split vaccine (6-35 month population).
Shenzhen Kangtai Biological Products: Announcement regarding the cancellation of the raised funds account.
Shenzhen Kangtai Biological Products: Announcement on the acceptance of clinical trial application for the quadrivalent influenza virus split vaccine (MDCK cell) of the company.
Shenzhen Kangtai Biological Products: Announcement of interest payment for convertible bonds of the company due in 2024.
Shenzhen Kangtai Biological Products: Announcement on Supplementary Pledge of Part of Shares by Controlling Shareholders and Actual Controllers
Shenzhen Kangtai Biological Products: Announcement of Resolutions of the 22nd Meeting of the 7th Board of Directors.
Shenzhen Kangtai Biological Products: Announcement regarding not adjusting the Kangtai Conversion 2 stock price downwards.
Shenzhen Kangtai Biological Products: Announcement of convertible bond conversion into stocks for the second quarter of 2024.
Shenzhen Kangtai Biological Products: Announcement Regarding the Potential Triggering of Conversion Price Adjustment Conditions for Kangtai Convertible Bonds
Shenzhen Kangtai Biological Products: 2021 Shenzhen Kangtai Biological Products Co., Ltd. issued convertible bonds on the Growth to unspecified objects. The 2024 tracking rating report of the CSI Enterprise Bond Index.
Shenzhen Kangtai Biological Products: Announcement Regarding Shareholding Commitment by the Company's Controlling Shareholder, Actual Controller, Shareholders Holding More Than 5% of Shares, Some Directors, Supervisors, and Senior Management Who Pledged Not to Reduce Shareholding of the Company.
No Data